Skip to main content

Table 1 Patients characteristics of MBC patients and IDC patients

From: The clinical features and prognosis of patients with mucinous breast carcinoma compared with those with infiltrating ductal carcinoma: a population-based study

Characteristics MBC N = 10,593 (%) IDC N = 402,797 (%) P
Sex    < 0.001
 Female 10,552 (99.6) 399,699 (99.2)  
 Male 41 (0.4) 3098 (0.8)  
Age    < 0.001
 < 60 years old 3395 (32.0) 208,149 (51.7)  
 ≥ 60 years old 7198 (68.0) 194,648 (48.3)  
Race    < 0.001
 White 8102 (76.5) 315,613 (78.4)  
 Black 1177 (11.1) 45,881 (11.4)  
 Other 1314 (12.4) 41,303 (10.3)  
Marital status    < 0.001
 Married 4993 (47.1) 224,449 (55.7)  
 Singled 5054 (47.7) 158,735 (39.4)  
 Unknown 546 (5.2) 19,613 (4.9)  
Location    < 0.001
 Central portion of breast 847 (8.0) 21,247 (5.3)  
 Upper-inner quadrant 1232 (11.6) 48,162 (12.0)  
 Lower-inner quadrant 977 (9.2) 22,735 (5.6)  
 Upper-outer quadrant 5318 (50.2) 229,970 (57.1)  
 Lower-outer quadrant 938 (8.9) 29,175 (7.2)  
 Unspecific 1281 (12.1) 51,508 (12.8)  
Grade    < 0.001
 I 5582 (52.7) 74,859 (18.6)  
 II 3335 (31.5) 159,214 (39.5)  
 III 389 (3.7) 150,305 (37.3)  
 IV 21 (0.2) 2554 (0.6)  
 Unspecific 1266 (12.0) 15,865 (3.9)  
SEER stage    < 0.001
 Local 9134 (86.2) 252,467 (62.7)  
 Regional 1137 (10.7) 127,795 (31.7)  
 Distant 197 (1.9) 18,965 (4.7)  
 Unspecific 125 (1.2) 3570 (0.9)  
T-stage    < 0.001
 T1 6732 (63.5) 234,608 (58.2)  
 T2 2816 (26.6) 119,558 (29.7)  
 T3 519 (4.9) 20,073 (5.0)  
 T4 207 (2.0) 16,860 (4.2)  
 Unspecific 320 (3.0) 11,698 (2.9)  
N-stage    < 0.001
 N0 9058 (85.5) 255,082 (63.3)  
 N1 822 (7.8) 93,750 (23.3)  
 N2 143 (1.3) 22,938 (5.7)  
 N3 99 (0.9) 15,704 (3.9)  
 Unspecific 471 (4.4) 15,323 (3.8)  
M-stage    < 0.001
 M0 10,202 (96.3) 379,350 (94.2)  
 M1 183 (1.7) 17,192 (4.3)  
 Unspecific 208 (2.0) 6255 (1.6)  
TNM stage    < 0.001
 I 6381 (60.2) 187,086 (46.4)  
 II 3183 (30.0) 139,311 (34.6)  
 III 402 (3.8) 45,608 (11.3)  
 IV 183 (1.7) 17,195 (4.3)  
 Unspecific 444 (4.2) 13,597 (3.4)  
ER    < 0.001
 Negative 187 (1.8) 83,543 (20.7)  
 Positive 9915 (93.6) 305,234 (75.8)  
 Unspecific 491 (4.6) 14,020 (3.5)  
PR    < 0.001
 Negative 1036 (9.8) 123,454 (30.6)  
 Positive 8958 (84.6) 262,619 (65.2)  
 Unspecific 599 (5.7) 16,724 (4.2)  
HER2    < 0.001
 Negative 5124 (48.4) 182,050 (45.2)  
 Positive 286 (2.7) 40,845 (10.1)  
 Unspecific 5183 (48.9) 179,902 (44.7)  
Molecular subtypes    < 0.001
 Luminal A 5088 (48.0) 153,463 (38.1)  
 Luminal B 255 (2.4) 28,240 (7.0)  
 HER2-enriched 30 (0.3) 12,517 (3.1)  
 Basal subtypes 29 (0.3) 28,371 (7.0)  
 Unspecific 5191 (49.0) 180,206 (44.7)  
Surgery    < 0.001
 No 580 (5.5) 25,525 (6.3)  
 Yes 9952 (93.9) 373,914 (92.8)  
  Partial mastectomy 6713 (63.4) 222,175 (55.2)  
  Total mastectomya 1878 (17.7) 75,800 (18.8)  
  Radical mastectomyb 1334 (12.6) 74,648 (18.5)  
  Unknown 27 (0.3) 1291 (0.3)  
 Unspecific 61 (0.6) 3358 (0.8)  
Radiotherapy    < 0.001
 No 5530 (52.2) 196,512 (48.8)  
 Yes 5063 (47.8) 206,285 (51.2)  
Survival    < 0.001
 5-year CSS rate 96.4 89.0  
 10-year CSS rate 93.4 83.8  
 Early stage 5-year CSS rate 97.67 92.00  
 Advanced stage 5-year CSS rate 38.81 27.70  
  1. aA simple mastectomy removes all breast tissue, the nipple, and areolar complex. An axillary dissection is not done
  2. bRadical mastectomy includes modified radical mastectomy, radical mastectomy NOS and extended radical mastectomy